Does dehydroepiandrosterone sulfate have a role in COVID-19 prognosis and treatment?
Endocr Regul
; 55(3): 174-181, 2021 Sep 13.
Article
in English
| MEDLINE | ID: covidwho-1408880
ABSTRACT
The pathophysiology of COVID comprises an exaggerated pro-inflammatory response. Hypothalamic-pituitary-adrenal (HPA) axis has a crucial role in various inflammatory conditions and modulated immunological response. Limited evidence is available regarding the incidence and the effect of HPA dysfunction in COVID-19. Although the cortisol levels have only been estimated in a few studies, the dehydroepiandrosterone sulfate (DHEAS) release from the adrenal gland has not been explored yet. In this mini review, the authors discuss the role of dehydroepiandrosterone (DHEA) and DHEAS in the acute stress response and immunological modulation. Various effects of DHEAS have been demonstrated in different diseases. The specific inhibitory effect of DHEA on interleukin 6 (IL-6) could be of paramount importance in COVID-19. Further, DHEA supplementation has already been proposed in inflammatory conditions, like rheumatoid arthritis. DHEAS levels in COVID-19 may help to understand the HPA axis dysfunction as well as the possibility of repurposing DHEA as a drug for mitigating the pro-inflammatory COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Dehydroepiandrosterone
/
Dehydroepiandrosterone Sulfate
/
COVID-19
/
COVID-19 Drug Treatment
/
Hypothalamo-Hypophyseal System
/
Immunologic Factors
Type of study:
Diagnostic study
/
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Endocr Regul
Journal subject:
Endocrinology
Year:
2021
Document Type:
Article
Affiliation country:
Enr-2021-0019
Similar
MEDLINE
...
LILACS
LIS